Atypical antipsychotics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Head-to-head comparison of the costs of atypical antipsychotics: a systematic review.CNS drugs · 2005
   Pooled it
2. Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study.World journal of psychiatry · 2025
   Article
3. Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.Schizophrenia bulletin · 2024
   Observational
4. Second-Generation Antipsychotics' Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders.Journal of clinical medicine · 2022
   Review
5. Predictors of switching antipsychotic medications in the treatment of schizophrenia.BMC psychiatry · 2010
   Article
6. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.PharmacoEconomics · 2006
   Article
7. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy.Social psychiatry and psychiatric epidemiology · 2005
   Article
8. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.PharmacoEconomics · 2004
   Review
9. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.Journal of psychiatry & neuroscience : JPN · 2003
   Review
10. Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.Clinical drug investigation · 2002
    Article
11. Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered.BMJ (Clinical research ed.) · 2001
    Article

Corrections and comments

• Commented on by
  Atypical antipsychotics in the treatment of schizophrenia. Paper underrates patients' experience of extrapyramidal symptoms.2001
• Commented on by
  Atypical antipsychotics in the treatment of schizophrenia. Paper corrupts concept of evidence based medicine.2001
• Commented on by
  Atypical antipsychotics in the treatment of schizophrenia. Users' views are important.2001
• Commented on by
  Atypical antipsychotics in the treatment of schizophrenia. Cost is a crucial issue.2001
• Comment on
  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.2000

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as